Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Basile

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 27, 2024
36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIOMichael J Bloch, Ajay J Kirtane, Michel Azizi, et al.
The American Journal of the Medical Sciences|June 17, 2005
Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndromeWilliam Bestermann, Mark C Houston, Jan Basile, et al.
The American Journal of the Medical Sciences|June 17, 2005
Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United StatesMark C Houston, Jan Basile, William H Bestermann, et al.
Diabetes Care|November 15, 2007
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Henry R Black, Barry Davis, Joshua Barzilay, et al.
Diabetes, Obesity & Metabolism|October 13, 2017
Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohortKathleen Dungan, Timothy E Craven, Kyaw Soe, et al.
Archives of Internal Medicine|November 15, 2006
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Joshua I Barzilay, Barry R Davis, Jeffrey A Cutler, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 19, 2008
National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diureticsElaine M Furmaga, Francesca E Cunningham, William C Cushman, et al.
Journal of Hypertension|May 7, 2020
Outcomes in adults with systolic blood pressure between 130 and 139 mmHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention TrialGabriel Contreras, Lingyi Lu, Leonardo Tamariz, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 16, 2006
Cardiovascular risk factor control in communities--update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' NetworkBrent M Egan, Daniel T Lackland, Priscilla Igho-Pemu, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 8, 2021
Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trialFelix Mahfoud, Michael J Bloch, Michel Azizi, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 27, 2024
36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIOMichael J Bloch, Ajay J Kirtane, Michel Azizi, et al.
The American Journal of the Medical Sciences|June 17, 2005
Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndromeWilliam Bestermann, Mark C Houston, Jan Basile, et al.
The American Journal of the Medical Sciences|June 17, 2005
Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United StatesMark C Houston, Jan Basile, William H Bestermann, et al.
Diabetes Care|November 15, 2007
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Henry R Black, Barry Davis, Joshua Barzilay, et al.
Diabetes, Obesity & Metabolism|October 13, 2017
Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohortKathleen Dungan, Timothy E Craven, Kyaw Soe, et al.
Archives of Internal Medicine|November 15, 2006
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Joshua I Barzilay, Barry R Davis, Jeffrey A Cutler, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 19, 2008
National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diureticsElaine M Furmaga, Francesca E Cunningham, William C Cushman, et al.
Journal of Hypertension|May 7, 2020
Outcomes in adults with systolic blood pressure between 130 and 139 mmHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention TrialGabriel Contreras, Lingyi Lu, Leonardo Tamariz, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 16, 2006
Cardiovascular risk factor control in communities--update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' NetworkBrent M Egan, Daniel T Lackland, Priscilla Igho-Pemu, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 8, 2021
Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trialFelix Mahfoud, Michael J Bloch, Michel Azizi, et al.
Pageof 8